A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women
Description
CONCLUSIONS: Vaccine formulations containing PT(gen) were safe and immunogenic in pregnant women. The ap1(gen) vaccine, with the lowest cost and reactogenicity, may be suitable for use in pregnant women when diphtheria and tetanus toxoids are not